With close to 30-40 basic screening tests available, the unit encompasses all the essential parameters typically covered in annual health check-ups
However, PAT growth will be lower than operating profit growth mainly due to brand amortization expenditure on account of acquisition.
Exothera will manufacture Meissa’s MV-012-968 vaccine candidate under CGMP regulations to supply Phase 2 clinical trials
The company has reported total income of Rs. 1682.45 crores during the period ended March 31, 2023
The company has reported total income of Rs. 11303.95 crores during the period ended March 31, 2023
The company has reported total income of Rs. 3276.35 crores during the period ended March 31, 2023
The company has reported total income of Rs. 880.59 crores during the period ended March 31, 2023
The company has reported total income of Rs. 2188.08 crores during the period ended March 31, 2023
The company has reported total income of Rs. 3928.8 crores during the period ended March 31, 2023
Eris Lifesciences has reported total income of Rs. 403.80 crores during the period ended March 31, 2023
Subscribe To Our Newsletter & Stay Updated
